The metrics one top biotech analyst says are key to whether states may have to take the next step and make tougher decisions

Matthew Harrison, Morgan Stanley's head of biotech research, discusses the worrying surge in COVID-19 cases in several states, and says if lockdown measures are reimposed in the U.S., they're likely to be more regionally-based than statewide or nationally.
Thu, Jun 25 20207:37 AM EDT